Gilead relinquishes orphan drug designation for potential COVID-19 treatment

Gilead Sciences has asked the US Food and Drug Administration to rescind an orphan drug designation for its experimental covid-19 treatment just days after the agency granted the status.

Get unlimited access to all Global Competition Review content